Additionally, our findings suggest that the combination of RNASET2 genetic markers and circulating protein levels may serve not only as a potential diagnostic tool in evaluating CD pathobiology but in addition help identify a subset of severe Crohn’s disease who may respond to RNASET2 as a novel therapeutic. Here, RNASET2 is linked to Cowden disease.